SIMTRIYO (Centanafadine) for ADHD: How the New ADHD Medication Works and How It Compares

TL;DR: What You Should Know About SIMTRIYO

SIMTRIYO (centanafadine) is a newly FDA-approved, once-daily medication for ADHD with a mechanism that is different from existing ADHD medications.

SIMTRIYO was approved by the FDA in July 2026 for ADHD in adults and in children ages 6 and older who weigh at least 20 kg, or about 44 pounds.

What makes SIMTRIYO particularly interesting is its pharmacology. Centanafadine inhibits the reuptake of three neurotransmitters: norepinephrine, dopamine, and serotonin. 

It is therefore described as a norepinephrine-dopamine-serotonin reuptake inhibitor, or NDSRI.

This is different from:

• Adderall and Vyvanse, which are amphetamine-based stimulants

• Ritalin and Concerta, which are methylphenidate-based stimulants

• Strattera, which primarily inhibits norepinephrine reuptake

• Qelbree, a non-stimulant with prominent noradrenergic and serotonergic effects

• Guanfacine and clonidine, which work through alpha-2 adrenergic receptors

One point that has caused some confusion is whether SIMTRIYO is a stimulant.

It is.

Although centanafadine is neither an amphetamine nor methylphenidate, the FDA classifies SIMTRIYO as a central nervous system stimulant. Its prescribing information also includes warnings regarding abuse, misuse, and addiction.

For adults, the recommended starting dose is 210 mg once each morning, which may be increased to 280 mg once daily depending on response and tolerability.

Clinical trials showed statistically significant improvement in ADHD symptoms, with separation from placebo beginning as early as the first week in studies.

However:

There is currently no good evidence showing that SIMTRIYO is better than Vyvanse, Adderall, Concerta, or other established ADHD medications.

Its major approval trials were primarily comparisons against placebo rather than direct comparisons against other ADHD medications.

For me, that is the best way to think about SIMTRIYO:

It is not a replacement for every existing ADHD medication. It is a genuinely different tool that gives clinicians another option for individualizing ADHD treatment.

What Is SIMTRIYO?

SIMTRIYO is the brand name for centanafadine, a medication developed for attention-deficit/hyperactivity disorder.

The FDA approved SIMTRIYO on July 24, 2026 for the treatment of ADHD in:

• Adults

• Adolescents ages 13–17

• Children ages 6–12 weighing at least 20 kg

SIMTRIYO is an extended-release capsule taken once daily in the morning.

It comes in:

• 140 mg capsules

• 210 mg capsules

• 280 mg capsules

For adults, treatment begins at 210 mg once daily and can be increased to a maximum recommended dose of 280 mg once daily based on clinical response and tolerability.

SIMTRIYO may be taken with or without food.

The capsule can also be opened and its contents sprinkled onto applesauce or yogurt or placed into a small amount of orange juice for patients who have difficulty swallowing capsules.

How Does SIMTRIYO Work?

Centanafadine inhibits three neurotransmitter transporters:

Norepinephrine transporter

Norepinephrine is involved in functions such as:

• Sustained attention

• Alertness

• Working memory

• Behavioral regulation

• Executive functioning

Dopamine transporter

Dopamine is involved in:

• Motivation

• Reward processing

• Attention

• Task initiation

• Reinforcement

• Goal-directed behavior

Serotonin transporter

Serotonin has broad effects on:

• Mood

• Anxiety

• Emotional processing

• Behavioral regulation

• Sleep

• Appetite

By inhibiting the transporters that normally remove these neurotransmitters from the synapse, centanafadine increases their availability.

The FDA notes that the exact mechanism through which centanafadine improves ADHD symptoms remains uncertain.

What is clear is that its combination of norepinephrine, dopamine, and serotonin reuptake inhibition is different from the mechanisms of currently established ADHD medications.

Why Is SIMTRIYO Different From Other ADHD Medications?

The most interesting feature of SIMTRIYO is not simply that it is new.

It is that it introduces a new pharmacologic mechanism into ADHD treatment.

For decades, ADHD medication treatment has largely been built around several major categories.

Amphetamines

Examples include:

• Adderall

• Adderall XR

• Vyvanse

• Dyanavel

• Mydayis

These predominantly increase dopamine and norepinephrine signaling.

Methylphenidates

Examples include:

• Ritalin

• Concerta

• Focalin

• Jornay PM

• Azstarys

These primarily inhibit dopamine and norepinephrine transporters.

Norepinephrine-focused non-stimulants

The best-known example is:

• Strattera (atomoxetine)

Other non-stimulants

These include:

• Qelbree (viloxazine ER)

• Guanfacine ER

• Clonidine ER

SIMTRIYO adds another category:

Norepinephrine + dopamine + serotonin reuptake inhibition

That does not automatically make SIMTRIYO stronger or better.

But it does mean someone who responds poorly to one medication mechanism may theoretically respond differently to centanafadine.

That matters because ADHD medication response varies substantially from person to person.

Is SIMTRIYO a Stimulant?

Yes. SIMTRIYO is classified by the FDA as a central nervous system stimulant.

This distinction is important because centanafadine was sometimes discussed during development as though it might occupy the non-stimulant category.

That is not how the approved medication is classified.

SIMTRIYO is unusual because it is:

• Not an amphetamine

• Not methylphenidate

• Not atomoxetine

• Not viloxazine

Yet it is still considered a CNS stimulant.

Its prescribing information contains warnings regarding abuse, misuse, and addiction, as do other stimulant medications.

So a patient specifically looking for a medication that avoids controlled-substance considerations should not automatically assume that SIMTRIYO fills the same role as Strattera or Qelbree.

Is SIMTRIYO a Controlled Substance?

SIMTRIYO has abuse potential and is intended to be federally controlled.

At the time of this article in August 2026, the medication was still undergoing final scheduling review by the U.S. Drug Enforcement Administration.

Otsuka has stated that commercial availability is expected later in 2026 following DEA scheduling.

The final controlled-substance schedule should therefore be confirmed once DEA scheduling is complete.

How Effective Is SIMTRIYO for Adult ADHD?

The adult ADHD evidence behind SIMTRIYO includes two large randomized, double-blind, placebo-controlled Phase 3 trials.

Together, the two studies randomized 906 adults between ages 18 and 55.

ADHD symptoms were measured using the Adult ADHD Investigator Symptom Rating Scale, or AISRS.

Across both trials, centanafadine produced significantly greater reductions in ADHD symptoms than placebo.

Depending on the study and dose, the placebo-adjusted improvement in AISRS score was approximately 2.7 to 4.4 points.

Clinical Global Impression-Severity scores also improved compared with placebo.

One technical detail is worth understanding: the pivotal adult trials originally studied a different sustained-release formulation of centanafadine. The FDA concluded that meaningful differences in effectiveness are not expected between those doses and the commercial SIMTRIYO 210 mg and 280 mg once-daily formulations.

The clinical development program also included pediatric and adolescent studies.

Overall, the evidence was sufficient for FDA approval across adults and pediatric patients ages 6 and older meeting the weight requirement.

How Quickly Does SIMTRIYO Work?

In clinical trials, improvement in ADHD symptoms was detectable as early as week one.

That is potentially significant.

Some traditional non-stimulant ADHD medications—particularly atomoxetine—may take several weeks before patients experience their full therapeutic benefit.

However, that does not mean everyone taking SIMTRIYO will know within seven days whether it is the right medication.

When I evaluate an ADHD medication, I am looking beyond whether someone simply “feels it.”

I want to know what happens to:

• Task initiation

• Sustained attention

• Distractibility

• Working memory

• Procrastination

• Impulsivity

• Emotional regulation

• Organization

• Productivity

• Follow-through

• Appetite

• Anxiety

• Sleep

• Heart rate

• Blood pressure

• Overall quality of life

The goal is not simply to produce a noticeable psychoactive effect.

The goal is meaningful functional improvement without unacceptable tradeoffs.

SIMTRIYO vs. Vyvanse

Vyvanse, or lisdexamfetamine, is one of the most commonly prescribed medications for adult ADHD.

Vyvanse is an amphetamine prodrug. The body converts lisdexamfetamine into dextroamphetamine.

Its primary effects involve dopamine and norepinephrine.

SIMTRIYO, by contrast, directly inhibits the reuptake of:

• Norepinephrine

• Dopamine

• Serotonin

Both medications are:

• Once-daily

• CNS stimulants

• Potentially capable of reducing appetite

• Potentially capable of causing insomnia

• Capable of affecting heart rate and blood pressure

But they are pharmacologically quite different.

Is SIMTRIYO better than Vyvanse?

We do not currently know.

There are not strong head-to-head trials demonstrating that SIMTRIYO is more effective than Vyvanse.

Vyvanse also has the advantage of many years of widespread clinical use.

SIMTRIYO's advantage is not established superiority. Its advantage is that it provides a different mechanism that may eventually be useful for patients who do not find the right balance with amphetamine-based medications.

SIMTRIYO vs. Adderall

Adderall contains mixed amphetamine salts.

Amphetamines increase dopamine and norepinephrine signaling through mechanisms that differ substantially from simple transporter blockade.

SIMTRIYO instead inhibits norepinephrine, dopamine, and serotonin reuptake.

Potential advantages of Adderall

Adderall has:

• Extensive clinical experience

• Strong evidence for ADHD symptom reduction

• Immediate-release and extended-release options

• Flexible dosing strategies

• Often rapid and noticeable effects

Potential reasons SIMTRIYO may eventually be considered

SIMTRIYO could become an alternative when:

• Amphetamine response is incomplete

• Side effects limit amphetamine treatment

• A patient responds differently to alternative pharmacology

• Another once-daily option is desired

But there is currently no basis for saying that SIMTRIYO is generally more effective than Adderall.

SIMTRIYO vs. Concerta, Ritalin, and Other Methylphenidates

Methylphenidate medications primarily inhibit:

• Dopamine reuptake

• Norepinephrine reuptake

SIMTRIYO inhibits those transporters plus the serotonin transporter.

That serotonin activity is one of its key distinguishing features.

Methylphenidate medications have decades of clinical experience and remain highly effective treatments for ADHD.

SIMTRIYO provides another option rather than making methylphenidate obsolete.

In someone who experiences excellent ADHD control on Concerta with minimal side effects, there may be little reason to switch simply because SIMTRIYO is newer.

SIMTRIYO vs. Strattera

Strattera, or atomoxetine, is a selective norepinephrine reuptake inhibitor.

It is considered a non-stimulant ADHD medication.

SIMTRIYO inhibits:

Norepinephrine + dopamine + serotonin.

SIMTRIYO is also classified as a stimulant, while Strattera is not.

This creates several important differences.

Strattera may be attractive when:

• Avoiding controlled substances is particularly important

• Stimulants are contraindicated

• Someone prefers a non-stimulant treatment

• Longer around-the-clock symptom coverage is desired

SIMTRIYO may eventually be attractive when:

• A different mechanism is needed

• Traditional stimulant mechanisms have not been ideal

• Atomoxetine has been ineffective or poorly tolerated

• Once-daily treatment is desired

SIMTRIYO should therefore not simply be thought of as “a better Strattera.”

They are substantially different medications.

SIMTRIYO vs. Qelbree

Qelbree is the brand name for viloxazine extended release.

Qelbree is an FDA-approved non-stimulant ADHD medication.

Viloxazine has prominent effects on norepinephrine along with more complex serotonergic effects.

SIMTRIYO directly inhibits the transporters for:

• Norepinephrine

• Dopamine

• Serotonin

The biggest practical distinction is that Qelbree is a non-stimulant, whereas SIMTRIYO is a CNS stimulant.

A person specifically trying to avoid a stimulant or controlled medication may therefore still favor Qelbree.

On the other hand, patients who have had incomplete benefit from established non-stimulants may eventually have another mechanism to consider with SIMTRIYO.

SIMTRIYO vs. Wellbutrin

Wellbutrin, or bupropion, is sometimes used off-label for ADHD.

Bupropion primarily affects:

• Norepinephrine

• Dopamine

SIMTRIYO affects:

• Norepinephrine

• Dopamine

• Serotonin

Bupropion can still be useful in selected patients, particularly when ADHD symptoms coexist with depression, but its ADHD efficacy is generally more modest than that of first-line stimulant treatments.

SIMTRIYO Compared With Common ADHD Medications

Medication	Main Mechanism	FDA Stimulant Classification?	Controlled?	Key Considerations
SIMTRIYO (centanafadine)	Norepinephrine, dopamine, and serotonin reuptake inhibition	Yes	DEA scheduling pending as of August 2026	Novel mechanism; once daily; limited real-world experience
Vyvanse	Amphetamine prodrug; increases dopamine and norepinephrine	Yes	Yes	Long acting; strong efficacy; extensive clinical experience
Adderall	Mixed amphetamine salts	Yes	Yes	Strong efficacy; flexible IR/XR dosing
Concerta/Ritalin	Dopamine and norepinephrine reuptake inhibition	Yes	Yes	Extensive evidence; many formulations
Strattera	Selective norepinephrine reuptake inhibition	No	No	Non-controlled; typically slower onset
Qelbree	Norepinephrine modulation with serotonergic effects	No	No	Non-controlled; once daily
Guanfacine ER	Alpha-2A adrenergic agonist	No	No	Can cause sedation and lower blood pressure
Clonidine ER	Alpha-2 adrenergic agonist	No	No	Often sedating; primarily used in pediatric ADHD
Bupropion	Norepinephrine-dopamine reuptake inhibition	No	No	Off-label for ADHD; may be useful with depression

What Are the Most Common SIMTRIYO Side Effects?

In adults, the most common adverse reactions reported in clinical studies included:

• Headache

• Decreased appetite

• Insomnia

• Nausea

• Dry mouth

• Diarrhea

Other reported effects included:

• Anxiety

• Irritability

• Abnormal dreams

• Increased heart rate

• Abdominal discomfort

• Rash

• Depressed mood

Not every patient will experience these effects, and medication tolerability can vary considerably between individuals.

Does SIMTRIYO Increase Heart Rate or Blood Pressure?

It can.

Like other CNS stimulants, SIMTRIYO can increase:

• Heart rate

• Blood pressure

The prescribing information recommends assessing cardiovascular history before treatment and monitoring heart rate and blood pressure during treatment, particularly after dose changes.

SIMTRIYO should generally be avoided in people with certain serious cardiac conditions, including significant structural heart disease, cardiomyopathy, serious arrhythmias, coronary artery disease, or other serious cardiac disease.

This is one reason I do not evaluate ADHD medications based solely on whether someone becomes more productive.

A medication that improves concentration but causes persistent hypertension, significant tachycardia, severe appetite suppression, or chronic insomnia may not represent successful treatment.

SIMTRIYO and Sleep

Insomnia is one of the more common adverse effects reported in adults taking centanafadine.

SIMTRIYO is therefore taken in the morning.

Sleep deserves much more attention in ADHD treatment than it often receives.

Chronic insufficient or fragmented sleep can independently impair:

• Attention

• Working memory

• Processing speed

• Emotional regulation

• Impulse control

• Motivation

• Executive functioning

Someone with untreated sleep apnea, chronic sleep restriction, restless legs syndrome, circadian disruption, or excessive caffeine use may appear to have more severe ADHD than they would under optimized sleep conditions.

Medication may still be appropriate, but simply escalating a stimulant without examining sleep can miss a significant part of the picture.

One Particularly Interesting SIMTRIYO Interaction: Caffeine

This is one of the aspects of SIMTRIYO that I find especially important in real-world treatment.

Centanafadine is a moderate inhibitor of CYP1A2.

CYP1A2 is one of the primary enzymes involved in metabolizing caffeine.

In a drug-interaction study, centanafadine did not significantly change the peak concentration of caffeine, but it approximately doubled total caffeine exposure over time after a 200 mg caffeine dose.

In practical terms, caffeine may potentially stay active longer or have a stronger cumulative effect in someone taking SIMTRIYO.

That becomes relevant for someone who regularly consumes:

• Multiple cups of coffee

• Cold brew

• Energy drinks

• Pre-workout products

• Caffeine tablets

A caffeine routine that was previously comfortable could potentially contribute to:

• Insomnia

• Anxiety

• Jitteriness

• Tremor

• Restlessness

• Increased heart rate

after SIMTRIYO is introduced.

This does not mean every person taking SIMTRIYO must stop drinking coffee.

It means caffeine should be treated as part of the medication plan rather than ignored because it is socially routine.

SIMTRIYO and Alcohol

SIMTRIYO has another unusual interaction worth knowing about.

The FDA prescribing information recommends avoiding alcohol at the same time as SIMTRIYO and for at least two hours after taking it.

Alcohol can alter the extended-release characteristics of the capsule and cause centanafadine to be released more rapidly.

That could theoretically produce:

• Greater exposure earlier in the day

• More exposure-related adverse effects

• Lower medication exposure later in the dosing interval

This is an example of why formulation matters—not just the medication molecule itself.

Can SIMTRIYO Be Taken With Antidepressants?

Potentially, but the medication combination should be reviewed carefully.

Because centanafadine affects serotonin, combining SIMTRIYO with other serotonergic drugs may increase the risk of serotonin syndrome.

Relevant medications can include certain:

• SSRIs

• SNRIs

• Tricyclic antidepressants

• Triptans

• Opioids with serotonergic properties

• Other serotonergic medications or supplements

This does not mean all antidepressant combinations are prohibited.

However, SIMTRIYO is contraindicated with monoamine oxidase inhibitors, or MAOIs, and at least 14 days should pass after stopping an MAOI before SIMTRIYO is started.

A complete medication and supplement review is therefore important.

SIMTRIYO and Anxiety: Could It Be Different From Other Stimulants?

This is an especially interesting area of emerging research.

Anxiety frequently coexists with adult ADHD, and stimulant treatment can be complicated when someone is particularly sensitive to anxiety or physical activation.

A 2026 randomized Phase 3b study evaluated centanafadine 280 mg once daily in 315 adults with ADHD plus generalized anxiety disorder and/or social anxiety disorder.

Participants taking centanafadine had significantly greater improvement in ADHD symptoms than participants taking placebo.

Interestingly, anxiety scores also improved more with centanafadine than with placebo.

That finding is encouraging, but it needs to be interpreted appropriately.

SIMTRIYO is not currently FDA approved as a treatment for anxiety disorders.

The anxiety findings came from a specific clinical trial population, and the improvement in anxiety was smaller than the improvement in ADHD symptoms.

I would therefore not describe SIMTRIYO as an “ADHD and anxiety medication.”

However, these results are clinically interesting because they suggest that having anxiety does not necessarily mean centanafadine will worsen it.

More research and real-world experience will help clarify which patients with ADHD and anxiety are most likely to do well on it.

Does SIMTRIYO Treat Depression?

SIMTRIYO is not FDA approved for depression.

The fact that centanafadine affects serotonin, norepinephrine, and dopamine may make it sound similar to an antidepressant.

But pharmacologic overlap does not establish clinical efficacy for a different disorder.

Depression should therefore still be evaluated and treated on its own merits rather than assuming SIMTRIYO will treat both ADHD and depression.

Other Important SIMTRIYO Safety Considerations

Abuse, misuse, and addiction

SIMTRIYO has abuse potential.

Before treatment, clinicians should consider a patient's history and risk for stimulant misuse or substance use disorders.

Mania and psychosis

Like other CNS stimulants, SIMTRIYO may precipitate new manic or psychotic symptoms in susceptible individuals.

A thoughtful ADHD evaluation should therefore include assessment for bipolar-spectrum illness and previous stimulant reactions.

Serotonin syndrome

Because centanafadine increases serotonergic signaling, serotonin syndrome is a potential risk when it is combined with other serotonergic medications.

Raynaud's phenomenon and peripheral vasculopathy

Peripheral circulation changes can occur with stimulant medications, including SIMTRIYO.

Tics and Tourette syndrome

Patients should be monitored for new or worsening motor or verbal tics.

Pediatric suicidal ideation and behavior

SIMTRIYO carries a boxed warning regarding suicidal ideation and behavior in pediatric patients.

Higher rates were observed among children ages 6–12 receiving SIMTRIYO compared with placebo.

Although my practice primarily focuses on adults, this remains important when discussing the medication's overall safety profile.

Who Might Be a Good Candidate for SIMTRIYO?

Because SIMTRIYO is so new, it is premature to claim that there is a clearly defined “ideal SIMTRIYO patient.”

Real-world clinical experience will tell us much more.

It may eventually be particularly worth considering in adults who:

• Have not found an optimal response with existing ADHD medications

• Have partial benefit from amphetamine or methylphenidate medications

• Experience limiting side effects with standard stimulants

• Have not responded adequately to atomoxetine or viloxazine

• Prefer once-daily medication

• May benefit from trying a pharmacologically distinct ADHD medication

• Have ADHD with comorbid anxiety where medication selection has been difficult

However, one point is important:

Clinical trials have not established that SIMTRIYO specifically works in people who have “failed” Vyvanse, Adderall, Concerta, Strattera, or Qelbree.

A different mechanism creates another possibility.

It does not guarantee a better response.

Who May Not Be a Good Candidate for SIMTRIYO?

SIMTRIYO may be inappropriate or require particular caution in people with:

• Serious cardiovascular disease

• Significant or uncontrolled hypertension

• Clinically significant tachycardia

• Previous stimulant-induced mania or psychosis

• Certain bipolar-spectrum presentations

• Significant stimulant misuse

• Complex serotonergic medication regimens

• Severe insomnia

• Significant sensitivity to appetite suppression

• Pheochromocytoma or a history of pheochromocytoma

It should not be used with an MAOI or within 14 days of stopping one.

As with any psychiatric medication, these decisions depend on the individual clinical situation.

Why I Don't Think There Is One “Best” ADHD Medication

People often ask:

What is the best ADHD medication?

The answer would be much easier if ADHD medication response were uniform.

It isn't.

One person may have a remarkable response to Vyvanse.

Another may become anxious and lose too much weight on it.

Someone may respond extremely well to Concerta after having a poor response to amphetamine.

Another may dislike both stimulant classes but do well on atomoxetine.

Another may tolerate Qelbree better.

And another may eventually find that a medication such as SIMTRIYO provides a balance that the established options did not.

This variability is why ADHD prescribing is more sophisticated than simply choosing whatever medication is newest.

I generally look for the medication that produces the best combination of:

• Symptom control

• Functional improvement

• Duration

• Emotional tolerability

• Sleep

• Appetite

• Cardiovascular tolerability

• Overall physical health

• Convenience

• Sustainability

The “strongest” medication is not necessarily the best medication.

My Integrative Approach to Adult ADHD Treatment

At Proactive Psychiatry, medication is an important part of ADHD treatment when appropriate.

But medication does not exist in isolation.

ADHD symptoms occur within a much larger biological, behavioral, and psychological system.

My approach to adult ADHD treatment is therefore integrative rather than medication-only.

That does not mean avoiding medication.

It means trying to optimize the entire system in which the medication is operating.

1. Sleep

Sleep is one of the first areas I pay attention to.

Poor sleep can worsen:

• Attention

• Memory

• Motivation

• Executive functioning

• Emotional regulation

• Anxiety

• Impulse control

When indicated, that may mean evaluating for issues such as:

• Chronic insufficient sleep

• Circadian rhythm disruption

• Sleep apnea

• Restless legs

• Medication-related insomnia

• Excessive caffeine

• Poor sleep timing

Sometimes patients need a medication adjustment.

Sometimes they need better sleep.

Often they need both.

2. Nutrition

ADHD medications can reduce appetite.

That becomes clinically important when someone begins:

• Skipping breakfast

• Missing lunch

• Eating too little protein

• Becoming dehydrated

• Losing excessive weight

• Binge eating late in the evening after medication wears off

Under-fueling during the day can contribute to fatigue, irritability, headaches, reduced exercise performance, and worsening cognition later in the day.

Nutrition is therefore not separate from ADHD medication management.

It can influence how well the medication works and how sustainable treatment becomes.

3. Exercise

Exercise has benefits that extend far beyond cardiovascular health.

Regular physical activity can support:

• Mood

• Sleep

• Stress regulation

• Cognitive function

• Executive functioning

• Cardiometabolic health

I generally think of exercise as complementary to ADHD treatment rather than as a substitute for appropriate medication.

4. Caffeine and Other Stimulants

Caffeine deserves more attention than it usually gets in psychiatric medication management.

Someone may tell me they take only one prescribed stimulant while simultaneously consuming:

• Three coffees

• An energy drink

• A pre-workout supplement

Those exposures matter.

With SIMTRIYO, this becomes particularly relevant because centanafadine can approximately double total caffeine exposure.

That makes a careful caffeine history especially useful.

5. Anxiety, Depression, and Emotional Regulation

Adults with ADHD frequently have other symptoms or conditions alongside it.

These can include:

• Anxiety

• Depression

• Burnout

• Emotional dysregulation

• Rejection sensitivity

• Chronic stress

• Trauma-related symptoms

The goal is not to attribute every psychological symptom to ADHD.

Sometimes ADHD drives secondary anxiety.

Sometimes anxiety independently worsens concentration.

Sometimes both are present.

Good treatment requires figuring out which is which.

6. Medical Contributors

When clinically appropriate, I also consider physical-health factors that can contribute to fatigue, cognitive symptoms, or difficulty concentrating.

Depending on the person's history, that may include evaluating for issues involving:

• Thyroid function

• Iron status

• Vitamin deficiencies

• Sleep disorders

• Medication effects

• Substance use

• Cardiometabolic health

This does not mean every person with ADHD needs dozens of laboratory tests.

Testing should be purposeful and guided by the clinical picture.

7. Executive-Function Systems

Medication can improve someone's capacity to focus and execute.

But it cannot automatically create:

• A workable calendar

• Better prioritization

• A task-management system

• Environmental structure

• Better habits

• Boundaries around distractions

• Realistic scheduling

Behavioral systems, coaching strategies, psychotherapy, and environmental design can therefore amplify what medication makes possible.

Medication Should Improve Your Life, Not Just Your ADHD Score

This distinction is important to me.

Someone could technically improve on an ADHD rating scale while simultaneously:

• Sleeping five hours per night

• Losing too much weight

• Becoming emotionally flat

• Feeling chronically anxious

• Developing elevated blood pressure

• Becoming excessively dependent on productivity

I would not consider that optimal treatment.

The goal should be broader.

I want medication to help someone function better while preserving or improving their overall health and quality of life.

That is part of what an integrative approach to ADHD means.

What I Find Most Interesting About SIMTRIYO

SIMTRIYO is interesting because it expands the pharmacologic toolkit.

It is not simply:

“another Adderall.”

It is not:

“a longer Vyvanse.”

And it is not:

“a new Strattera.”

Centanafadine introduces a different combination of neurotransmitter effects into FDA-approved ADHD treatment.

That matters because ADHD itself is heterogeneous.

Two people can meet exactly the same diagnostic criteria while responding very differently to the same medication.

The existence of another pharmacologically distinct treatment gives clinicians another way to personalize care.

Where SIMTRIYO ultimately belongs in the treatment sequence remains to be seen.

New Does Not Automatically Mean Better

Whenever a new psychiatric medication becomes available, enthusiasm tends to move faster than long-term clinical experience.

SIMTRIYO has several genuinely interesting qualities:

• A novel mechanism

• Once-daily dosing

• FDA approval across adults and pediatric patients

• Evidence of symptom improvement beginning early in treatment

• Emerging data in adults with ADHD and comorbid anxiety

But there are also important unknowns.

We have decades of clinical experience with medications such as amphetamine and methylphenidate.

We do not yet have decades of experience with centanafadine.

Questions that will become clearer over time include:

• Which patients respond best?

• How does it compare directly with Vyvanse or Concerta?

• How often do patients discontinue it in real-world practice?

• How significant are caffeine interactions clinically?

• What will insurance coverage look like?

• Where will it fall in insurance formularies?

• How expensive will it be?

• Will insurers require trials of older ADHD medications first?

• How will patients perceive its duration and consistency throughout the day?

• Will its serotonergic activity provide meaningful advantages for certain ADHD presentations?

Those answers require time.

My approach is therefore neither:

“It's new, so everyone should switch to it.”

nor:

“We already have ADHD medications, so we don't need anything new.”

Instead:

SIMTRIYO is another promising tool, and now we need to determine where that tool works best.

SIMTRIYO and Adult ADHD Treatment in Washington, DC

For adults seeking ADHD treatment in Washington, DC, the arrival of SIMTRIYO is another example of why ADHD medication management should involve more than choosing between Adderall and Vyvanse.

A comprehensive adult ADHD evaluation should consider:

• Whether ADHD is actually present

• Which ADHD symptoms create impairment

• Childhood history

• Work and relationship functioning

• Psychiatric history

• Anxiety and depression

• Bipolar-spectrum symptoms

• Previous medication trials

• Sleep

• Caffeine and substance use

• Cardiovascular history

• Physical health

• Nutrition

• Exercise

• Treatment goals

At Proactive Psychiatry, I take an individualized and integrative approach to adult ADHD treatment.

Medication can be an extremely effective part of treatment.

But the goal is not merely to make someone feel more stimulated.

The goal is to improve:

• Attention

• Executive function

• Task initiation

• Emotional regulation

• Follow-through

• Work performance

• Relationships

• Overall health

• Quality of life

while minimizing unnecessary physiological and psychological costs.

SIMTRIYO may eventually become an important option for selected adults who need a different approach.

Frequently Asked Questions About SIMTRIYO

What is SIMTRIYO?

SIMTRIYO is the brand name for centanafadine, a once-daily extended-release medication approved by the FDA in July 2026 for ADHD in adults and children ages 6 and older who meet the minimum weight requirement.

What is centanafadine?

Centanafadine is the active ingredient in SIMTRIYO. It inhibits the reuptake of norepinephrine, dopamine, and serotonin and is known as a norepinephrine-dopamine-serotonin reuptake inhibitor, or NDSRI.

Is SIMTRIYO a stimulant?

Yes. The FDA classifies SIMTRIYO as a central nervous system stimulant, even though it is neither an amphetamine nor methylphenidate.

Is SIMTRIYO a non-stimulant?

No.

This is an important misconception.

Although centanafadine has a different mechanism from traditional amphetamine and methylphenidate medications, its FDA prescribing information identifies it as a CNS stimulant.

Is SIMTRIYO a controlled substance?

SIMTRIYO has abuse potential and is intended to be federally controlled. As of August 2026, final DEA scheduling was still pending.

When will SIMTRIYO be available?

SIMTRIYO received FDA approval in July 2026. Otsuka has stated that commercial availability is expected later in 2026 following final DEA scheduling.

What dose of SIMTRIYO do adults take?

The recommended adult starting dose is 210 mg once daily in the morning.

The dose can be increased to 280 mg once daily based on response and tolerability.

How long does SIMTRIYO take to work?

In clinical studies, differences from placebo in ADHD symptoms appeared as early as the first week.

Individual response can vary, and determining whether a medication is a good long-term fit usually requires evaluating both symptom improvement and tolerability over time.

How long does SIMTRIYO last?

SIMTRIYO is formulated as a once-daily extended-release medication intended to provide treatment across the day.

Real-world patient experience regarding duration will become clearer as more people begin taking the medication after commercial launch.

Is SIMTRIYO better than Vyvanse?

There is currently no strong evidence demonstrating that SIMTRIYO is generally superior to Vyvanse.

The medications work differently, and individual response may vary.

Is SIMTRIYO better than Adderall?

No head-to-head evidence currently establishes SIMTRIYO as superior to Adderall.

SIMTRIYO provides a different pharmacologic mechanism rather than a proven stronger one.

Is SIMTRIYO like Strattera?

Not exactly.

Strattera primarily inhibits norepinephrine reuptake and is a non-stimulant.

SIMTRIYO inhibits norepinephrine, dopamine, and serotonin reuptake and is classified as a stimulant.

Is SIMTRIYO like Qelbree?

Both medications involve norepinephrine and serotonin biology, but their mechanisms are different.

Qelbree is considered a non-stimulant. SIMTRIYO is classified as a CNS stimulant.

What are the most common SIMTRIYO side effects in adults?

Common adverse reactions include:

• Headache

• Decreased appetite

• Insomnia

• Nausea

• Dry mouth

• Diarrhea

Can SIMTRIYO cause anxiety?

It can.

Anxiety was reported in some patients during clinical development.

However, a Phase 3b trial in adults with ADHD and comorbid anxiety found improvement in both ADHD and anxiety measures compared with placebo.

SIMTRIYO is not currently FDA approved for treating anxiety disorders.

Can SIMTRIYO cause insomnia?

Yes.

Insomnia was among the most common adverse reactions reported in adult clinical trials.

That is one reason SIMTRIYO is taken in the morning.

Can SIMTRIYO decrease appetite?

Yes.

Decreased appetite was one of the more common adverse effects reported in clinical studies.

Can SIMTRIYO raise blood pressure?

Yes.

Like other CNS stimulants, SIMTRIYO can increase heart rate and blood pressure.

Heart rate and blood pressure should be evaluated as part of treatment.

Can I drink coffee while taking SIMTRIYO?

Possibly, but caffeine deserves particular attention with SIMTRIYO.

Centanafadine inhibits CYP1A2, and a clinical interaction study found that it approximately doubled overall caffeine exposure after a 200 mg caffeine dose.

Some people may therefore need to reduce caffeine intake depending on effects on sleep, anxiety, heart rate, or jitteriness.

Can I drink alcohol with SIMTRIYO?

The prescribing information recommends avoiding alcohol at the same time as SIMTRIYO and for at least two hours afterward.

Alcohol may interfere with the medication's extended-release formulation and cause centanafadine to be released more rapidly.

Can SIMTRIYO be taken with an SSRI?

Potentially, but the combination should be reviewed by the prescribing clinician.

SIMTRIYO has serotonergic activity, so combining it with other serotonergic medications can increase the risk of serotonin syndrome.

Can SIMTRIYO be taken with Wellbutrin?

There is not a universal yes-or-no answer.

Both medications can influence catecholamine signaling and may have overlapping effects on areas such as heart rate, blood pressure, anxiety, appetite, or sleep.

The combination would require individualized medication review.

Can SIMTRIYO treat anxiety and ADHD at the same time?

SIMTRIYO is approved for ADHD, not anxiety.

A 2026 Phase 3b study in adults with ADHD plus generalized and/or social anxiety found improvement in both ADHD and anxiety measures compared with placebo.

Those results are encouraging, but they do not make SIMTRIYO an FDA-approved anxiety treatment.

Does SIMTRIYO treat depression?

SIMTRIYO is not FDA approved for depression.

Its effects on serotonin, dopamine, and norepinephrine should not be interpreted as proof that it functions as an antidepressant.

Could SIMTRIYO work if Vyvanse or Adderall didn't?

Possibly.

SIMTRIYO uses a different pharmacologic mechanism, so a poor response to amphetamine does not necessarily predict a poor response to centanafadine.

However, clinical trials have not established that SIMTRIYO specifically works better in people who previously failed Vyvanse or Adderall.

Could SIMTRIYO work if Strattera didn't?

Potentially.

SIMTRIYO has significant dopamine and serotonin activity in addition to norepinephrine reuptake inhibition, so its mechanism differs substantially from atomoxetine.

Again, a different mechanism creates another option but does not guarantee a response.

Is SIMTRIYO the best ADHD medication?

There is no single ADHD medication that is best for everyone.

The best medication depends on factors including:

• Symptoms

• Previous medication response

• Side effects

• Sleep

• Anxiety

• Appetite

• Cardiovascular health

• Substance-use risk

• Duration needs

• Lifestyle

• Treatment goals

SIMTRIYO expands the available options rather than replacing every medication that came before it.

The Bottom Line

SIMTRIYO is one of the most interesting additions to ADHD pharmacology in years.

Instead of simply introducing another formulation of amphetamine or methylphenidate, centanafadine introduces a distinct mechanism:

norepinephrine + dopamine + serotonin reuptake inhibition.

That makes SIMTRIYO genuinely different.

It does not yet make it demonstrably better.

SIMTRIYO is still a stimulant.

It can affect:

• Appetite

• Sleep

• Heart rate

• Blood pressure

It has abuse potential.

It has clinically relevant considerations involving:

• Caffeine

• Alcohol

• Serotonergic medications

And we do not yet have evidence demonstrating that it is universally superior to established treatments such as Vyvanse, Adderall, methylphenidate, Strattera, or Qelbree.

Its real significance is that it provides another biologically distinct option.

For patients who have struggled to find the right balance between effectiveness and tolerability with existing ADHD medications, another mechanism is valuable.

That is how I think about ADHD treatment more broadly.

Medication matters.

But medication is only one component of a system that also includes sleep, nutrition, exercise, cardiovascular health, emotional health, executive-function strategies, environment, and the individual's goals.

The goal is not simply better concentration.

The goal is better functioning, better health, and a treatment plan that remains effective and sustainable over time.

Looking for ADHD treatment or an ADHD evaluation in Washington DC, New York, or Colorado?

Book an appointment with me today!

References

1. U.S. Food and Drug Administration. SIMTRIYO (centanafadine) Prescribing Information. Revised July 2026.

2. U.S. Food and Drug Administration. Novel Drug Approvals for 2026. SIMTRIYO (centanafadine), approved July 24, 2026.

3. Otsuka Pharmaceutical Development & Commercialization, Inc. FDA approval announcement for SIMTRIYO (centanafadine), July 24, 2026.

4. Adler LA, et al. Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder: Results of Two Phase 3 Randomized Clinical Trials.

5. Otsuka Pharmaceutical Development & Commercialization, Inc. Phase 3b study of centanafadine in adults with ADHD and comorbid anxiety, 2026.

This article is provided for educational purposes and is not a substitute for individualized medical evaluation or treatment. Medication decisions should be based on a person's diagnosis, medical and psychiatric history, other medications and supplements, potential risks and interactions, and treatment goals.